Natco Pharma also plans to launch a pen device version in April 2026, priced between ₹4,000 and ₹4,500 per month, depending on dosage.

Claudio Galimberti, Chief Economist & Global Director of Market Analysis at Rystad Energy says supply bottlenecks and slow production recovery could keep energy markets volatile…

The fall in copper price was expected, not the timing and pace. Despite its vital role in the world’s digital transition, near-term prices may remain…

Discounts on physical gold in India narrowed due to festival buying and global price corrections. Rajesh Rokde noted a 10% sales increase during Gudi Padwa.

Citi upgraded Dr Lal Pathlabs Ltd to ‘buy’ from ‘sell’, targeting ₹1,650 per share. The diagnostics sector has stabilized, with expected 10-12% organic revenue growth…

Varun Lohchab, Head of Institutional Research at HDFC Securities, says metals remain a tactical play with limited upside after the recent rally, as the firm…

Brokerage firm Jefferies maintained its “buy” rating on HDFC Bank with a price target of ₹1,240, which implies an upside potential of 59% from current…

Aurobindo Pharma’s subsidiary, Apitoria Pharma, received a ‘Voluntary Action Indicated’ (VAI) classification from the USFDA for its Telangana facility after a December 2025 inspection.

CMPDI offers services that range from coal and mineral exploration, mine planning & design services, environmental services, laboratory services, coal beneficiations services and mine closure…

36 analysts have coverage on Tata Steel, 23 of them have a “buy” rating, seven say “hold”, while six have a “sell” rating on the…